RHUMBLINE ADVISERS - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,381,239
-35.8%
82,809
+6.3%
0.00%0.0%
Q2 2023$2,151,901
+125156.2%
77,911
+4.3%
0.00%0.0%
Q1 2023$1,718
+121.4%
74,709
+5.0%
0.00%
+100.0%
Q4 2022$776
-99.9%
71,153
+0.9%
0.00%0.0%
Q3 2022$594,000
+12.7%
70,517
+5.9%
0.00%0.0%
Q2 2022$527,000
-52.0%
66,566
+43.4%
0.00%0.0%
Q1 2022$1,099,000
-26.9%
46,426
+5.6%
0.00%
-50.0%
Q4 2021$1,504,000
+98.7%
43,969
+3.0%
0.00%
+100.0%
Q3 2021$757,000
-58.7%
42,695
+4.6%
0.00%
-50.0%
Q2 2021$1,832,000
+113.0%
40,812
+22.9%
0.00%
+100.0%
Q1 2021$860,000
+26.5%
33,215
-1.5%
0.00%0.0%
Q4 2020$680,000
+18.1%
33,735
+14.6%
0.00%0.0%
Q3 2020$576,000
+9.9%
29,446
-0.8%
0.00%0.0%
Q2 2020$524,000
+344.1%
29,676
+78.0%
0.00%
Q1 2020$118,000
+2.6%
16,671
+2.3%
0.00%
Q4 2019$115,000
-38.5%
16,291
+4.8%
0.00%
Q3 2019$187,000
+19.9%
15,540
+20.7%
0.00%
Q2 2019$156,000
+77.3%
12,878
+25.1%
0.00%
Q1 2018$88,000
-50.6%
10,294
+2.0%
0.00%
Q3 2017$178,000
+56.1%
10,096
+0.2%
0.00%
Q2 2017$114,00010,0760.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$43,400,0003.81%
BVF INC/IL 3,901,759$69,139,0002.70%
COMMODORE CAPITAL LP 498,079$8,826,0002.33%
Altium Capital Management LP 346,000$6,131,0001.61%
Twin Lakes Capital Management, LLC 139,287$2,468,0001.45%
Opaleye Management Inc. 330,222$5,852,0001.09%
EcoR1 Capital, LLC 1,443,800$25,584,0000.89%
OBERMEYER WOOD INVESTMENT COUNSEL, LLLP 776,689$13,763,0000.76%
JABODON PT CO 90,656$1,606,0000.66%
Artal Group S.A. 1,500,000$26,580,0000.60%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders